Developing oncolytic Herpes simplex virus type 1 through UL39 knockout by CRISPR-Cas9

OBJECTIVE(S): Oncolytic Herpes simplex virus type 1 (HSV-1) has emerged as a promising strategy for cancer therapy. However, development of novel oncolytic mutants has remained a major challenge owing to low efficiency of conventional genome editing methods. Recently, CRISPR-Cas9 has revolutionized...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Iran J Basic Med Sci
Autores principales: Ebrahimi, Saeedeh, Makvandi, Manoochehr, Abbasi, Samaneh, Azadmanesh, Kayhan, Teimoori, Ali
Formato: Artigo
Lenguaje:Inglês
Publicado: Mashhad University of Medical Sciences 2020
Materias:
Original Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7395182/
https://ncbi.nlm.nih.gov/pubmed/32774817
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.22038/ijbms.2020.43864.10286
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares